We are live on
!
Find out more
TA
Tamarack Advisers Portfolio holdings
AUM
$2.12M
1-Year Est. Return
58.09%
This Fund
S&P 500
This Quarter
Est. Return
+11.89%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$318M
AUM Growth
+$57.2M
(+22%)
Cap. Flow
+$31.1M
Cap. Flow
% of AUM
9.77%
Top 10 Holdings %
Top 10 Hldgs %
65.15%
Holding
46
New
18
Increased
7
Reduced
10
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PDCO
Patterson Companies, Inc.
PDCO
|
+$25.6M |
| 2 |
WBA
Walgreens Boots Alliance
WBA
|
+$16.3M |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
+$13.5M |
| 4 |
Pacira BioSciences
PCRX
|
+$8.23M |
| 5 |
CORV
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
|
+$8.02M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
IMPR
IMPRIVATA, INC COM
IMPR
|
+$18.3M |
| 2 |
Quest Diagnostics
DGX
|
+$14.7M |
| 3 |
Labcorp
LH
|
+$9.77M |
| 4 |
NVRO
NEVRO CORP.
NVRO
|
+$6.06M |
| 5 |
DexCom
DXCM
|
+$5.16M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.3% |
| 2 | Miscellaneous | 2% |
| 3 | Communication Services | 1.14% |
| 4 | Real Estate | 0.56% |
| 5 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ELGX
1
DELISTED
Endologix Inc
ELGX
| $35.7M | 11.24% |
288,650
-2,350
| -0.8% | -$301K |
|
|
NXTM
2
DELISTED
NxStage Medical Inc.
NXTM
| $26.6M | 8.37% |
1,075,000
-125,000
| -10% | -$2.91M |
|
|
PDCO
3
DELISTED
Patterson Companies, Inc.
PDCO
| $24.7M | 7.78% |
545,000
+540,250
| +11,374% | +$25.6M |
|
|
ARIA
4
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| $24.7M | 7.76% |
1,850,000
-250,000
| -12% | -$2.51M |
|
5
Bio-Rad Laboratories Class A
BIO
$10.3B
| $17.5M | 5.51% |
108,000
+38,000
| +54% | +$5.77M |
|
|
MDRX
6
DELISTED
Veradigm Inc. Common Stock
MDRX
| $16.7M | 5.26% |
1,285,000
+275,000
| +27% | +$3.68M |
|
|
WBA
7
DELISTED
Walgreens Boots Alliance
WBA
| $16M | 5.04% |
+200,000
| New | +$16.3M |
|
8
Steris
STE
$21.9B
| $15.9M | 5.01% |
220,000
+35,000
| +19% | +$2.47M |
|
|
HOLX
9
DELISTED
Hologic
HOLX
| $15M | 4.73% |
390,000
+55,000
| +16% | +$2.08M |
|
|
10
Pacira BioSciences
PCRX
$1.05B
| $14.2M | 4.46% |
400,000
+210,000
| +111% | +$8.23M |
|
|
SPNC
11
DELISTED
Spectranetics Corp
SPNC
| $12.3M | 3.87% |
500,000
-214,200
| -30% | -$5M |
|
|
12
Jazz Pharmaceuticals
JAZZ
$16B
| $12.1M | 3.8% |
+100,000
| New | +$13.5M |
|
13
Alkermes
ALKS
$7.73B
| $10.5M | 3.32% |
225,000
-8,000
| -3% | -$380K |
|
|
LMNX
14
DELISTED
Luminex Corp
LMNX
| $10.3M | 3.25% |
460,000
-66,000
| -13% | -$1.44M |
|
15
Medtronic
MDT
$121B
| $9.88M | 3.11% |
115,000
-54,000
| -32% | -$4.71M |
|
|
CORV
16
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
| $6.94M | 2.18% |
+2,200,000
| New | +$8.02M |
|
17
NovoCure
NVCR
$2.09B
| $6.56M | 2.06% |
+775,000
| New | +$7.07M |
|
|
CORI
18
DELISTED
Corium International, Inc.
CORI
| $6.12M | 1.93% |
1,065,000
-10,000
| -0.9% | -$50.3K |
|
|
QTNT
19
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $5.89M | 1.85% |
+18,750
| New | +$5.27M |
|
20
Teladoc Health
TDOC
$1.14B
| $5.82M | 1.83% |
+325,000
| New | +$5.7M |
|
|
MODN
21
DELISTED
MODEL N, INC.
MODN
| $3.63M | 1.14% |
335,000
+315,000
| +1,575% | +$3.69M |
|
22
Option Care Health
OPCH
$3.63B
| $2.45M | 0.77% |
+208,713
| New | +$2.25M |
|
23
AtriCure
ATRC
$2.62B
| $2.1M | 0.66% |
135,000
-201,000
| -60% | -$3.09M |
|
|
STRM
24
DELISTED
Streamline Health Solutions
STRM
| $2.05M | 0.64% |
75,867
| – | – |
|
|
ARA
25
DELISTED
American Renal Associates Holdings, Inc
ARA
| $1.77M | 0.56% |
+100,000
| New | +$2.25M |
|
Similar funds
SCM
LBC
ICM
LCMP
GIP
STC
GC
DU
Tamarack Advisers's Q3 2016 Portfolio in Review
As of Q3 2016, Tamarack Advisers held 46 positions worth $318M, up 22% from $261M the previous quarter. Its ten largest holdings account for 65% of the portfolio.
Tamarack Advisers deployed $31.1M of net new capital in Q3 2016, opening 18 new positions and adding to 7 existing holdings. Its largest new stake was Walgreens Boots Alliance: 200,000 shares worth $16M.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 90% a quarter earlier, followed by Miscellaneous and Communication Services.
On the sell side, the largest reduction was Quest Diagnostics, an estimated $14.7M trimmed.
- Tamarack Advisers's largest Q3 2016 buy was Walgreens Boots Alliance: 200,000 shares worth $16M.
- Tamarack Advisers added most to Patterson Companies, Inc. in Q3 2016, an estimated $25.6M increase.
- Tamarack Advisers's biggest Q3 2016 reduction was Quest Diagnostics, cutting an estimated $14.7M.
- Tamarack Advisers fully exited IMPRIVATA, INC COM in Q3 2016, selling an estimated $18.3M.
- Tamarack Advisers's ten largest holdings make up 65% of its $318M portfolio in Q3 2016.
- Tamarack Advisers opened 18 new positions and closed 9 in Q3 2016.
- Tamarack Advisers's portfolio value rose 22% quarter-over-quarter to $318M.
Based on Tamarack Advisers's 13F filing for Q3 2016, filed 9 Nov 2016.